All Brands Owned by CSL Behring (CSL Limited)

What does CSL Behring own?
CSL Behring owns a portfolio of plasma-derived therapy brands including Privigen, Hizentra, Kcentra, Haegarda, Streptase, and albumin products. As part of CSL Limited, it is associated with CSL Seqirus (influenza vaccines including Afluria and Flucelvax) and CSL Vifor (Ferinject and Venofer for iron deficiency). CSL Plasma operates the world's largest plasma collection network with over 300 centers.

Is CSL Behring publicly traded?
CSL Behring is a division of CSL Limited, which trades on the Australian Securities Exchange under ticker CSL. CSL Limited is a component of the S&P/ASX 20 Index. The company completed its IPO in June 1994 at A$2.30 per share. CSL Behring itself is not separately listed but contributes the majority of CSL Limited's revenue.

Who founded CSL?
CSL was founded in 1916 by the Australian government as Commonwealth Serum Laboratories, a federal body focused on vaccine manufacture. William Penfold, recruited from the Lister Institute in London, served as the first director. The organization was privatized in 1994 by the Keating government and listed on the Australian Securities Exchange.

What is CSL Behring's main business?
CSL Behring develops, manufactures, and markets plasma-derived therapies for rare and serious diseases. Its primary products are immunoglobulins for immune deficiencies, albumin for shock and burns, and clotting factors for hemophilia. The division is the core earnings driver for CSL Limited, generating the majority of the group's revenue from chronic disease patients requiring lifelong treatment.

What were CSL's FY2025 financial results?
CSL Limited reported FY2025 (fiscal year ended June 2025) revenue of US$15.6 billion, up 5.1% from FY2024. Net income was US$3.0 billion, and underlying profit (NPATA) increased 14% to US$3.3 billion on a constant currency basis. The company declared dividends of US$1.62 per share, a 12% increase from FY2024.

What happened with the Vifor acquisition?
CSL acquired Vifor Pharma for $11.7 billion in 2022, adding iron deficiency and nephology treatments to its portfolio. The acquisition has underperformed expectations, with generic competition in iron products and the revocation of marketing authorization for Tavenos. FY2026 impairment charges related to Vifor and other assets totaled US$5.4 billion, contributing to a net loss of US$2.58 billion.

What is the Seqirus demerger plan?
In August 2026, CSL announced plans to demerge its CSL Seqirus influenza vaccine business into a separately listed entity. Management framed the separation as giving Seqirus autonomy to pursue opportunities in the vaccines market. However, the plan was subsequently put on hold after the company determined that proceeding would not maximize shareholder value.